As of 2024-12-15, the Intrinsic Value of CytomX Therapeutics Inc (CTMX) is
0.88 USD. This CTMX valuation is based on the model Peter Lynch Fair Value.
With the current market price of 1.11 USD, the upside of CytomX Therapeutics Inc is
-20.40%.
CTMX Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(21.25) - (6.01) |
(9.31) |
-938.5% |
| DCF (Growth 10y) |
(8.55) - (28.38) |
(12.85) |
-1257.9% |
| DCF (EBITDA 5y) |
(1.87) - (2.26) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(3.51) - (4.16) |
(1,234.50) |
-123450.0% |
| Fair Value |
0.88 - 0.88 |
0.88 |
-20.40% |
| P/E |
1.00 - 4.87 |
2.04 |
83.9% |
| EV/EBITDA |
1.96 - 2.45 |
2.19 |
97.2% |
| EPV |
(11.93) - (14.19) |
(13.06) |
-1276.4% |
| DDM - Stable |
1.71 - 6.65 |
4.18 |
276.3% |
| DDM - Multi |
0.90 - 2.76 |
1.36 |
22.9% |
CTMX Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
86.87 |
| Beta |
1.21 |
| Outstanding shares (mil) |
78.26 |
| Enterprise Value (mil) |
46.29 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.82% |
| Cost of Debt |
5.00% |
| WACC |
6.75% |